These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 26406408)

  • 1. Clinicopathological significance of β -tubulin isotype III gene expression in breast cancer patients.
    He Q; Peng B; Zhuang D; Xiao L; Zheng L; Fan Z; Zhu J; Xu B; Xu C; Zhao J; Wu L; Zhou P; Hou L; Yu F; Zhao G
    Cancer Biomark; 2015; 15(6):823-31. PubMed ID: 26406408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
    Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S
    J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-4728-3p could act as a marker of HER2 status.
    Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
    Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
    Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
    Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.
    Pentheroudakis G; Batistatou A; Kalogeras KT; Kronenwett R; Wirtz RM; Bournakis E; Eleftheraki AG; Pectasides D; Bobos M; Papaspirou I; Kamina S; Gogas H; Koutras AK; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2011 May; 127(1):179-93. PubMed ID: 21390496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women.
    Watrowski R; Castillo-Tong DC; Wolf A; Schuster E; Fischer MB; Speiser P; Zeillinger R
    Anticancer Res; 2015 Nov; 35(11):5901-4. PubMed ID: 26504013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
    Khabaz MN
    Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast Cancer in Men: a Report from the Department of Radiation Oncology in Kermanshah Province, Iran.
    Amirifard N; Sadeghi E
    Asian Pac J Cancer Prev; 2016; 17(5):2593-6. PubMed ID: 27268636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis.
    Fujiwara S; Ibusuki M; Yamamoto S; Yamamoto Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):472-81. PubMed ID: 23100016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-negative breast cancers: unique clinical presentations and outcomes.
    Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA
    Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy.
    Mohammad AM; Abdel HA; Abdel W; Ahmed AM; Wael T; Eiman G
    Indian J Cancer; 2006; 43(4):163-8. PubMed ID: 17192687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers.
    Yagi T; Inoue N; Yanai A; Murase K; Imamura M; Miyagawa Y; Enomoto Y; Nishimukai A; Takatsuka Y; Hirota S; Akazawa K; Miyoshi Y
    Breast Cancer; 2016 Mar; 23(2):224-30. PubMed ID: 25082658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
    Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
    Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
    Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
    Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
    Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
    Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.